Clinical Research
Clinical trials provide the newest treatment options to doctors and patients in the fight against cancer.
The Department of Radiation Oncology enrolls as many as 160 new patients each year in clinical trials. Faculty members hold leadership positions in the Radiation Therapy Oncology Group (RTOG), which develops and oversees all national radiation oncology trials funded by the National Cancer Institute.
For more information, talk to your doctor or contact the Clinical Research Office at 214-645-7322.
Breast
STU 052018.052 (GammaPod Boost) Tumor Bed Boost Using a Breast-Specific Radiosurgery Device, the GammaPod: Registry Study and Evaluation of Quality of Life with Development of Sizing Nomogram. Learn about the GammaPod.
STU 2024.0561 (RAPS) Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-Stage ER+ Breast Cancer.
Gastrointestinal
STU 2024-0601 (ULTRAS) Ultra-High-Dose Radiation for Liver Metastasis Using MR-Guided Treatment with Stereotactic Ablative Single-Fraction (ULTRAS): Phase III Randomized Controlled Trial.
STU 2024.0475 (Morpheus) A Phase III Study Testing Two Dose Escalation Strategies to Increase the Population of Complete Responders After Radiation Therapy in the Context of Organ Preservation for Patients With Rectal Cancer.
STU 20252048 (NRG-GI011) A Phase III Randomized Trial of Dose-Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100).
STU20260105 (EXPAND) EXtending Outcomes for PAncreas Cancer Patients with Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
Genitourinary
NRG-GU015 (ARCHER) The Phase III Adaptive Radiation and Chemotherapy for Muscle-invasive Bladder Cancer Trial.
STU 2024.0024 A Study of a Non-Significant Risk (NSR) Device: [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on the RefleXion X1 System in Patients Already Undergoing Diagnostic PET PSMA Imaging.
STU 2024.0919 (SPARK) STING Agonist and Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy in Combination with Checkpoint Inhibition for Patients with Metastatic Kidney Cancer.
STU 2025-1220 (RANGER) Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy.
Gynecological
Please check back for open gynecological trials.
Head and Neck
STU 2023.0715 (G-FORCE) Phase II Randomized Study of Glottic Larynx Hypofractionated Radiotherapy Versus Conventional Radiotherapy.
STU 2024.0603 (INVERT) Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy.
STU 2024.0171 (KEVLARx) A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx.
Lung
STU 022015.069 (JoLT-Ca/STABLEMATES) A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC), the STABLEMATES Trial. Learn more about the JoLT-CA/STABLEMATES trial.
STU 2024.1215 Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung.
Other
ASPECT Study Assessment of SIGNATERA genome PErformance across Cancer Types.